RGBPP — what changed in the latest 10-Q
A section-by-section comparison of RGBPP's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-14 vs the prior 10-Q · 2026-02-13
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +19 | −6 | ~6 | 3 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings, Risk factors, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-14
Operating Expense were $212,774 for the three months ended March 31, 2026 and $ 172,414 for the same period ended 2025. The primary operating expense for 2026 consists of $ 178,454 of Consulting & Professional expenses. In the same period in previous year Consulting and Professional fees expenditure…
Revenues from continuing operations were $118,129 for the six months ended March 31, 2026 which is essentially equivalent to Revenues from continuing operations for the same period ended 2025. $54,849 of revenue from related parties recognized during the six months ended March 31, 2026 consisted of …
Operating Expense were $823,462 for the six months ended March 31, 2026 and $ 292,857 for the same period ended 2025. The primary operating expense for 2026 consists of $ 332,218 of Consulting & Professional expenses. In the same period in previous year Consulting and Professional fees expenditure w…
Research and Development Expenses of $212,216 recognized by the Company for the six months ended March 31, 2026 consisted of :
(a)$2,216 paid for Patent maintenance services provided by the Company’s patent attorney.
Text removed vs the prior filing · source: 10-Q · 2026-02-13
Operating Expense were $610,689 for the three months ended December 31, 2025 and $ 120,443 for the same period ended 2024. The primarily operating expenses for 2025 consists of $ 210,000 of Research and Development expenses and $231,925 of General and Administrative Expenses. In the same period in p…
Working capital deficit increased by $291,814 from September 30, 2025 to December 31, 2025, primarily due to increase in Derivative Liability.
Net increase (decrease) in cash and cash equivalents $(64,977) $(581)
Net cash used in operating activities for the three months ended December 31, 2025 was $197,941 compared to $66,379, for the same period ended 2024. The increase in cash used in operating activities is primarily attributable to increased operating expenses incurred by the Company during the three mo…
Net cash generated by financing activities for the three months ended December 30, 2025 was $132,964 which consisted of proceeds from sales of newly issued common stock.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice